Patent analysis of Bruton's tyrosine kinase inhibitor ibrutinib / 国际药学研究杂志

The aim of this paper is to analyze the global patent layout of ibrutinib, the patent layout of key themes, and the original research company's patent layout of ibrutinib, so as to provide a reference for the related domestic drug companies to be acquainted with the patent status of the drug, and to select and decide their breakthrough points and market competition strategies. In this study, the drug name and drug structure were used as keywords for search in the patent databases CNABS and DWPI, and the results were combined with the search results from the International Online Search System STN. Then, the patent with ibrutinib as the invention point was selected and used for further analysis. Pharmacyclics has applied for 26 patents on ibrutinib in China, and the subject matter relates to compounds, compositions, new uses, dosage forms, preparation methods and so on. Among them, 4 patents have been granted, 8 patents have been rejected or overdue, and 14 patent applications are still pending. In order to break through the patent barriers of ibrutinib, Chinese pharmaceutical companies should always pay much attention to the patent approval process and the expiration status of patents from the original research company, and make full use of the intellectual property system to effectively protect their own innovations.

Current situation and consideration of patent protection in classical representative famous prescriptions in China / 中国中药杂志

Classical Representative Famous Prescription is the valuable cultural heritage of Chinese medicine. In November 2018,the State Council issued the " Intensive Implementation of the National Intellectual Property Strategy in 2018 to Accelerate the Construction of IP Strong Country",explicitly proposing to strengthen the intellectual property protection of Classical Representative Famous Prescription.How about the current situation of intellectual property protection of lassical Representative Famous Prescription in China? We selected Liuwei Dihuang Pills,Shengmai Powder and Guizhi Fuling Pills( three representative drugs on market) from Chinese Pharmacopoeia2015 Volume I issued by Chinese Pharmacopoeia Commission to analyze their patent layout,reflecting its status quo of patent protection as follows: first,in recent years,the number of related patent applications for Classical Representative Famous Prescriptions has declined,which was positively correlated with the drug registration and approval policies in recent years,but the policy dividend has not been reflected in the patent application,which may be related to the long period of pharmaceutical R&D; secondly,the patent applicant in the field of Chinese medicine is mainly based on individuals,but the applicant of Classical Representative Famous Prescription is mainly of enterprises,and in addition,the company applicants have the highest authorization rate; thirdly,the main technologies are to improve preparation method and the dosage form in the research and development of Classical Representative Famous Prescription,but these two types of authorized patents have much difficulty in further application on the market. Therefore,the innovative entities shall look for a new breakthrough in secondary development and utilization of Classical Representative Famous Prescriptions.

Empirical Study on TCM Patents Layout Based on Patent Function / 中国药学杂志

OBJECTIVE: To provide a method for objectively analyzing the level of companies' patent layout. It is of great significance for companies to study and adjust the strategy of patent layout in-depth study on the characteristics of TCM patent layout at home and abroad. METHODS: A two-dimensional quadrant bubble map was constructed based on the patent layout quantity and quality indicators, analyze the level of original patents and improved patents layout at home and abroad, select companies with high level of patent layout, and further analyze the above-mentioned companies' patent layout strategy. RESULTS: The greater the number of patents does not necessarily mean that the higher the level of patent layout of companies; the layout of original patents and improved patents comprehensively reflect the level of patent layout of companies; high-level patent layout of companies because of their own characteristics reflect the companies' differences in the patent layout strategy. CONCLUSION: Companies should pay attention to the quality and quantity of the patent layout at the same time, and formulate corresponding patent layout strategies according to their own characteristics.

Patent strategy of Chinese materia medica industry in process of modernization / 中草药

Chinese materia medica (CMM) is well-respected nowadays. Multinational pharmaceutical companies have grabbed huge market profits by implementing patent strategies, while we can see there are many problems in the protection of the intellectual property rights in CMM enterprises in China. Such as the consciousness on patent protection is not strong, the plan and management of patent mining is not reasonable, the layout of patent is not scientific, and so on, which seriously affects the development of the CMM industry. So the patent mining, the collection mechanism of inventive concept, collaboration applications of the types of patent layout have been discussed and studied in this paper, in order to promote the patent strategies to be effectively applied in the CMM industry in the process of modernization.